
Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis

Join Dr. Kwatra outlining the micro itch cycle involving type 2 cell polarization and cytokines that directly affect fibroblasts to cause more immune dysregulation in PN.

Learn about type 2 inflammation as a driver of neurosensitization and chronic itch in atopic dermatitis with this educational tool.

Join Drs. Elmariah, Kim, and Metz as they explore the latest research on neuro-immune mechanisms driving chronic itch and inflammation in PN and CSU.

Join Dr. Shawn Kwatra in discussing the diverse clinical presentations of PN and the role of type 2 inflammation in disease pathogenesis.

Join Dr Kwatra as he dives deeper into the mechanism of lesion formation in Prurigo Nodularis and the impact the development of these skin lesions have on patient life.
An infographic exploring the pathophysiology of prurigo nodularis and the role of type 2 inflammation.

Professor and Stiefel-endowed Chair of Medical Dermatology at the Dr. Phillip Frost Department of Dermatology at the Miller School of Medicine at the University of Miami; Director of the Miami Itch Center, Florida, US

In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Christine Bangert discusses how type 2 inflammation contributes to epidermal barrier dysfunction and chronic itch in AD
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Enno Schmidt highlights the role of type 2 cytokines involved in the dysregulated Type 2 immune responses that contribute to inflammation and subsequent itch in bullous pemphigoid.

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
Join ADVENT for an educational symposium on PN at WCI 2025!